[53] STEVENSON W G, HERNANDEZ A F, CARSON P E, et al. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee [J].J Card Fail, 2012, 18(2): 94-106.DOI: 10.1061/j.cardfail, 2011.12.004.

[54] BAX J J, ABRAHAM T, BAROLD S S, et al.Cardiac resynchronization therapy: Part 1—issues before device implantation [J].J Am Coll Cardiol, 2005, 46(12): 2153-2167.DOI: 10.1061/j.jacc.2005.09.019.

[55] CHUNG E S, LEON A R, TAVAZZI L, et al.Results of the Predictors of Response to CRT (PROSPECT) trial [J]. Circulation, 2008, 117(20): 2608-2616.DOI: 10.1161/CIRCULATIONAHA.107.743120.

[56] STEFFEL J, ROBERSON M, SINGH J P, et al.The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial [J].Eur Heart J, 2015, 36(30): 1983-1989.DOI: 10.1093/eurheartj/ehv242.

[57] ROSE E A, GELIJNS A C, MOSKOWITZ A J, et al.Long-term use of a left ventricular assist device for end-stage heart failure [J]. N Engl J Med, 2001, 345(20): 1435-1443.DOI: 10.1056/NEJMoal012175.

[58] YANG F, KORMOS R L, ANTAKI J F.High-speed visualization of disturbed pathlines in axial flow ventricular assist device under pulsatile conditions[J].J Thorac Cardiovasc Surg, 2015, 150(4): 938-944.DOI: 10.1016/j.jtcvs.2015.06.049.

[59] ESTEP J D, STARLING R C, HORSTMANSHOF D A, et al.Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: Results From the ROADMAP Study [J].J Am Coll Cardiol, 2015, 66(16): 1747-1761.DOI: 10.1016/j.jacc.2015.07.075.

[60] KIRKLIN J K, NAFTEL D C, PAGANI F D, et al.Sixth INTERMACS annual report: a 10, 000-patient database [J]. J Heart Lung Transplant, 2014, 33(6): 555-564.DOI: 10.1016/j.healun.2014.04.010.

[61] YUAN N, ARNAOUTAKIS G J, GEORGE T J, et al.The spectrum of complications following left ventricular assist device placement [J].J Card Surg, 2012, 27(5): 630-638.DOI: 10.1111/j.1540-8191, 2012.01504.x.

[62] CORNWELL W K 3rd, TARUMI T, AENGEVAEREN V L, et al.Effect of pulsatile and nonpulsatile flow on cerebral perfusion in patients with left ventricular assist devices [J].J Heart Lung Transplant, 2014, 33(11): 1295-1303.DOI: 10.1016/j.healun, 2014.08.013.

[63] ABRAHAM W T, STOUGH W G, PIÑA I L, et al.Trials of implantable monitoring devices in heart failure: which design is optimal ? [J].Nat Rev Cardiol, 2014, 11(10): 576-585. DOI: 10.1038/nrcardio.2014.114.

[64] CONRAADS V M, SPRUIT M A, BRAUNSCHWEIG F, et al. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure[J].Circ Heart Failure, 2014, 7(2): 279-287.DOI: 10.1161/CIRCHEARTFAIURE.113.000883.

[65] ADAMSON P B, SMITH A L, ABRAHAM W T, et al.Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device[J].Circulation, 2004, 110(16): 2389-2394.DOI: 10.1161/01.CIR.0000139841.42454.78.

[66] CATANZARITI D, LUNATI M, LANDOLINA M, et al.Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure [J].Pacing Clin Electrophysiol, 2009, 32(3): 363-370.DOI: 10.1111/j.1540-8159.2008.02245.x.

[67] WHELLAN D J, OUSDIGIAN K T, Al-KHATIB S M, et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study [J].J Am Coll Cardiol, 2010, 55(17): 1803-1810.DOI: 10.1061/j.jacc.2009.11.089.

[68] SMALL R S, WHELLAN D J, BOYLE A, et al.Implantable device diagnostics on day of discharge identify heart failure patients at increased risk for early readmission for heart failure [J].Eur J Heart Fail, 2014, 16(4): 419-425.DOI: 10.1002/ejhf.48.

[69] ABRAHAM W T, ADAMSON P B, BOURGE R C, et al.Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial[J].Lancet, 2011, 377(9766): 658-666.DOI: 10.1061/S0140-6736(11)60101-3.

[70] GWATHMEY J K, YEREVANIAN A, HAJJAR R J.Targeting sarcoplasmic reticulum calcium ATPase by gene therapy [J]. Hum Gene Ther, 2013, 24(11): 937-947.DOI: 10.1089/hum.2013.2512.

[71] CHAUDHRI B B, DEL MONTE F, HARDING S E, et al.Gene transfer in cardiac myocytes[J].Surg Clin North Am, 2004, 84(1): 141-159, ix-x.DOI: 10.1016/S0039-6109(03)00209-3.

[72] DEL MONTE F, WILLIAMS E, LEBECHE D, et al.Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca^{2+}-ATPase in a rat model of heart failure [J]. Circulation, 2001, 104(12): 1424-1429.DOI: 10.1161/hc3601.095574.

[73] BYRNE M J, POWER J M, PREOVOLOS A, et al.Recirculating cardiac delivery of AAV2/ISERCA2a improves myocardial function in an experimental model of heart failure in large animals [J].Gene Ther, 2008, 15(23): 1550-1557.DOI: 10.1038/gt.2008.120.

[74] KAWASE Y, LY H Q, PRUNIER F, et al.Reversal of cardiac dysfunction after long-term expression of SERCA 2a by gene transfer in a pre-clinical model of heart failure [J].J Am Coll Cardiol, 2008, 51(11): 1112-1119.DOI: 10.1016/j.jacc.2007.12.014.